Exposure–Response Modeling and Simulation of Progression‐Free Survival and Adverse Events of Sorafenib Treatment in Patients With Advanced Thyroid Cancer

Sorafenib is an oral multikinase inhibitor approved for the treatment of differentiated thyroid carcinoma (DTC), renal cell carcinoma, and hepatocellular carcinoma. In the phase III DECISION trial in patients with DTC, sorafenib exposure and the incidence of some adverse events (AEs) were higher tha...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Transl Sci
Autors principals: Grevel, Joachim, Jentsch, Garrit, Austin, Rupert, Prins, Nicolaas H., Lettieri, John, Mitchell, David, Huang, Funan, Brose, Marcia S., Schlumberger, Martin, Meinhardt, Gerold, Peña, Carol E. A., Ploeger, Bart A.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2019
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6742948/
https://ncbi.nlm.nih.gov/pubmed/30920122
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cts.12634
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars